REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...
VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...
What's happening: Temperatures are forecast to reach the 90s, pushing cooling systems to run longer and use more energy to maintain indoor temperaturesWhy it...
Kaylea Arnett and James Lichtenstein claim victory as more than 50,000 fans attend Florida's first-ever Red Bull Cliff Diving World Series event.ST. PETERSBURG, Fla.,...
AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...
Monmouth County's Premier Home Design Destination Invites the Community to an Evening of Celebration on June 8, 2026MONMOUTH COUNTY, N.J., June 5, 2026 /PRNewswire/...
The article outlines common warning signs that may help homeowners identify plumbing leaks before major water damage develops.CLINTON, Iowa, June 5, 2026 /PRNewswire/ --...